Get the Stockscreener App
11.27
0.99%
0.11
Nurix Therapeutics Inc stock is traded at $11.27, with a volume of 595.14K.
It is up +0.99% in the last 24 hours and down -0.97% over the past month.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
See More
Previous Close:
$11.16
Open:
$11.35
24h Volume:
595.14K
Relative Volume:
0.64
Market Cap:
$881.28M
Revenue:
$54.55M
Net Income/Loss:
$-193.57M
P/E Ratio:
-3.8997
EPS:
-2.89
Net Cash Flow:
$-181.86M
1W Performance:
-2.51%
1M Performance:
-0.97%
6M Performance:
-53.94%
1Y Performance:
-11.47%
1-Day Range:
$11.18
$11.56
1-Week Range:
$11.05
$11.72
52-Week Range:
$8.18
$29.56
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Name
Nurix Therapeutics Inc
Sector
Industry
Phone
(415) 660-5320
Address
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Compare NRIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
11.27 | 881.28M | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-25 | Initiated | Leerink Partners | Market Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-11-24 | Initiated | Jefferies | Buy |
| Sep-06-24 | Resumed | Robert W. Baird | Outperform |
| Jul-31-24 | Initiated | Truist | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-09-23 | Initiated | Barclays | Overweight |
| Feb-28-23 | Initiated | Oppenheimer | Outperform |
| Oct-11-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Dec-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-30-21 | Resumed | Piper Sandler | Overweight |
| Apr-30-21 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Nov-19-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | Stifel | Buy |
View All
Nurix Therapeutics Inc Stock (NRIX) Latest News
(NRIX) Trading Signals - news.stocktradersdaily.com
JPMorgan Chase & Co. Reduces Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Darwin Global Management Ltd. Takes $3.08 Million Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Price T Rowe Associates Inc. MD Lowers Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix therapeutics’ chief scientific officer sells $38,841 in stock By Investing.com - Investing.com Canada
Nurix therapeutics’ chief scientific officer sells $38,841 in stock - Investing.com
Nurix Therapeutics Executives Sell Shares for Tax Obligations - TradingView
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Purchased by Lord Abbett & CO. LLC - MarketBeat
T. Rowe Price Investment Management Inc. Sells 167,663 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Breaking Down Nurix Therapeutics: 7 Analysts Share Their Views - Benzinga
Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs - The Manila Times
Russell Investments Group Ltd. Grows Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Up 6.4%Here's Why - MarketBeat
Nurix Therapeutics reports breakthroughs in cancer drug research - Investing.com Australia
Jump Financial LLC Purchases New Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics Presents Positive Preclinical Data at the AAC - GuruFocus
Nurix Therapeutics Showcases Promising Preclinical Data for BTK, BRAF, and Aurora A Kinase Degraders at AACR 2025 Annual Meeting - Nasdaq
Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets - The Manila Times
Revolutionary Brain-Penetrant Cancer Drugs Outperform Competitors: 10,000 Proteins Destroyed Per Hour - Stock Titan
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $30.44 Average Price Target from Analysts - MarketBeat
Geode Capital Management LLC Acquires 137,087 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap DownWhat's Next? - MarketBeat
Affinity Asset Advisors LLC Raises Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Wasatch Advisors LP Lowers Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Fmr LLC Grows Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Trexquant Investment LP - MarketBeat
(NRIX) Technical Data - news.stocktradersdaily.com
Nurix advances IRAK4 degrader into Phase 1 trials with FDA nod - Investing.com Canada
Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential - Seeking Alpha
Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher - simplywall.st
Nurix advances IRAK4 degrader into Phase 1 trials with FDA nod By Investing.com - Investing.com South Africa
Nurix Therapeutics (NRIX) Advances Experimental Drug Following FDA Clearance - GuruFocus
Nurix gets FDA clearance to initiate trial for its anti-inflammatory drug candidate - Seeking Alpha
FDA Clears IND for Nurix's (NRIX) IRAK4 Degrader, Phase 1 Trial Set for 2025 | NRIX Stock News - GuruFocus
Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479a Novel IRAK4 Degrader for Inflammatory Conditions - The Manila Times
Nurix Therapeutics Announces FDA Clearance for GS-6791/NX-0479 IND, Phase 1 Trials Set to Begin in Q2 2025 in Collaboration with Gilead Sciences - Nasdaq
FDA Green Lights Groundbreaking IRAK4 Degrader: $420M Milestone Potential in Inflammatory Disease Fight - Stock Titan
Leerink Partnrs Has Optimistic Outlook of NRIX Q2 Earnings - MarketBeat
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates - MSN
NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program - MSN
Vanguard Group Inc. Boosts Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Norges Bank Makes New $6.01 Million Investment in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics Inc Stock (NRIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
2.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):